vs
EXACT SCIENCES CORP（EXAS）与Snowflake Inc.（SNOW）财务数据对比。点击上方公司名可切换其他公司
Snowflake Inc.的季度营收约是EXACT SCIENCES CORP的1.4倍（$1.2B vs $878.4M），EXACT SCIENCES CORP净利率更高（-9.8% vs -24.2%，领先14.5%），Snowflake Inc.同比增速更快（28.7% vs 23.1%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $113.6M），过去两年Snowflake Inc.的营收复合增速更高（25.1% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Snowflake Inc.是美国云数据平台服务商，创立于加利福尼亚州圣马特奥，总部位于蒙大拿州博兹曼。旗下平台支持数据分析功能，可实现数据集的低延迟并发访问，服务运行在亚马逊云科技、微软Azure、谷歌云三大公有云平台上。
EXAS vs SNOW — 直观对比
营收规模更大
SNOW
是对方的1.4倍
$878.4M
营收增速更快
SNOW
高出5.6%
23.1%
净利率更高
EXAS
高出14.5%
-24.2%
自由现金流更多
EXAS
多$6.8M
$113.6M
两年增速更快
SNOW
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.2B |
| 净利润 | $-86.0M | $-294.0M |
| 毛利率 | 70.1% | 67.8% |
| 营业利润率 | -9.4% | -27.2% |
| 净利率 | -9.8% | -24.2% |
| 营收同比 | 23.1% | 28.7% |
| 净利润同比 | 90.1% | 9.4% |
| 每股收益（稀释后） | $-0.45 | $-0.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASSNOW
| Q4 25 | $878.4M | $1.2B | ||
| Q3 25 | $850.7M | $1.1B | ||
| Q2 25 | $811.1M | $1.0B | ||
| Q1 25 | $706.8M | $986.8M | ||
| Q4 24 | $713.4M | $942.1M | ||
| Q3 24 | $708.7M | $868.8M | ||
| Q2 24 | $699.3M | $828.7M | ||
| Q1 24 | $637.5M | $774.7M |
净利润EXASSNOW
| Q4 25 | $-86.0M | $-294.0M | ||
| Q3 25 | $-19.6M | $-298.0M | ||
| Q2 25 | $-1.2M | $-430.1M | ||
| Q1 25 | $-101.2M | $-327.5M | ||
| Q4 24 | $-864.6M | $-324.3M | ||
| Q3 24 | $-38.2M | $-316.9M | ||
| Q2 24 | $-15.8M | $-317.0M | ||
| Q1 24 | $-110.2M | $-169.4M |
毛利率EXASSNOW
| Q4 25 | 70.1% | 67.8% | ||
| Q3 25 | 68.6% | 67.5% | ||
| Q2 25 | 69.3% | 66.5% | ||
| Q1 25 | 70.8% | 66.2% | ||
| Q4 24 | 69.0% | 65.9% | ||
| Q3 24 | 69.4% | 66.8% | ||
| Q2 24 | 69.8% | 67.1% | ||
| Q1 24 | 70.0% | 68.8% |
营业利润率EXASSNOW
| Q4 25 | -9.4% | -27.2% | ||
| Q3 25 | -3.0% | -29.7% | ||
| Q2 25 | -0.3% | -42.9% | ||
| Q1 25 | -13.6% | -39.2% | ||
| Q4 24 | -122.8% | -38.8% | ||
| Q3 24 | -5.6% | -40.9% | ||
| Q2 24 | -3.8% | -42.1% | ||
| Q1 24 | -16.7% | -35.6% |
净利率EXASSNOW
| Q4 25 | -9.8% | -24.2% | ||
| Q3 25 | -2.3% | -26.0% | ||
| Q2 25 | -0.1% | -41.3% | ||
| Q1 25 | -14.3% | -33.2% | ||
| Q4 24 | -121.2% | -34.4% | ||
| Q3 24 | -5.4% | -36.5% | ||
| Q2 24 | -2.3% | -38.3% | ||
| Q1 24 | -17.3% | -21.9% |
每股收益（稀释后）EXASSNOW
| Q4 25 | $-0.45 | $-0.87 | ||
| Q3 25 | $-0.10 | $-0.89 | ||
| Q2 25 | $-0.01 | $-1.29 | ||
| Q1 25 | $-0.54 | $-0.98 | ||
| Q4 24 | $-4.69 | $-0.98 | ||
| Q3 24 | $-0.21 | $-0.95 | ||
| Q2 24 | $-0.09 | $-0.95 | ||
| Q1 24 | $-0.60 | $-0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.1B |
| 总资产 | $5.9B | $8.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASSNOW
| Q4 25 | $964.7M | $1.9B | ||
| Q3 25 | $1.0B | $1.9B | ||
| Q2 25 | $858.4M | $2.2B | ||
| Q1 25 | $786.2M | $2.6B | ||
| Q4 24 | $1.0B | $2.1B | ||
| Q3 24 | $1.0B | $1.3B | ||
| Q2 24 | $946.8M | $1.3B | ||
| Q1 24 | $652.1M | $1.8B |
股东权益EXASSNOW
| Q4 25 | $2.4B | $2.1B | ||
| Q3 25 | $2.5B | $2.4B | ||
| Q2 25 | $2.5B | $2.4B | ||
| Q1 25 | $2.4B | $3.0B | ||
| Q4 24 | $2.4B | $2.9B | ||
| Q3 24 | $3.2B | $4.1B | ||
| Q2 24 | $3.2B | $4.6B | ||
| Q1 24 | $3.1B | $5.2B |
总资产EXASSNOW
| Q4 25 | $5.9B | $8.2B | ||
| Q3 25 | $5.9B | $8.2B | ||
| Q2 25 | $5.8B | $8.2B | ||
| Q1 25 | $5.7B | $9.0B | ||
| Q4 24 | $5.9B | $8.2B | ||
| Q3 24 | $6.7B | $6.9B | ||
| Q2 24 | $6.7B | $7.3B | ||
| Q1 24 | $6.4B | $8.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $137.5M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $113.6M |
| 自由现金流率自由现金流/营收 | 13.7% | 9.4% |
| 资本支出强度资本支出/营收 | 3.6% | 2.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $776.7M |
8季度趋势，按日历期对齐
经营现金流EXASSNOW
| Q4 25 | $151.7M | $137.5M | ||
| Q3 25 | $219.9M | $74.9M | ||
| Q2 25 | $89.0M | $228.4M | ||
| Q1 25 | $30.8M | $432.7M | ||
| Q4 24 | $47.1M | $101.7M | ||
| Q3 24 | $138.7M | $69.9M | ||
| Q2 24 | $107.1M | $355.5M | ||
| Q1 24 | $-82.3M | $344.6M |
自由现金流EXASSNOW
| Q4 25 | $120.4M | $113.6M | ||
| Q3 25 | $190.0M | $58.2M | ||
| Q2 25 | $46.7M | $183.4M | ||
| Q1 25 | $-365.0K | $421.4M | ||
| Q4 24 | $10.7M | $88.3M | ||
| Q3 24 | $112.6M | $64.8M | ||
| Q2 24 | $71.2M | $338.9M | ||
| Q1 24 | $-120.0M | $331.5M |
自由现金流率EXASSNOW
| Q4 25 | 13.7% | 9.4% | ||
| Q3 25 | 22.3% | 5.1% | ||
| Q2 25 | 5.8% | 17.6% | ||
| Q1 25 | -0.1% | 42.7% | ||
| Q4 24 | 1.5% | 9.4% | ||
| Q3 24 | 15.9% | 7.5% | ||
| Q2 24 | 10.2% | 40.9% | ||
| Q1 24 | -18.8% | 42.8% |
资本支出强度EXASSNOW
| Q4 25 | 3.6% | 2.0% | ||
| Q3 25 | 3.5% | 1.5% | ||
| Q2 25 | 5.2% | 4.3% | ||
| Q1 25 | 4.4% | 1.1% | ||
| Q4 24 | 5.1% | 1.4% | ||
| Q3 24 | 3.7% | 0.6% | ||
| Q2 24 | 5.1% | 2.0% | ||
| Q1 24 | 5.9% | 1.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
SNOW
| Products | $1.2B | 96% |
| Professional Services And Other | $54.5M | 4% |
| Related Party | $6.7M | 1% |
